Our Innovative Medicines business is made up of two separate commercial organizations, Innovative Medicines International and Innovative Medicines US.

Core therapeutic areas

  • Cardiovascular

    Cardiovascular disease is a global health crisis. Billions of people are affected physically, emotionally and financially. Thanks to a combination of our legacy, global footprint and leading science, Novartis is uniquely positioned to help change this landscape. Our efforts include use of early interventions and development of pioneering treatments, from prevention to management, as well as the creation of innovative access models. Our goal is to reduce and ultimately stop premature death and disability from cardiovascular disease.
  • Hematology

    Novartis is deeply committed to transforming the lives of people living with blood cancers and life-threatening blood disorders. Together with its research partners – Novartis led the era of targeted therapies in cancer and, in investigating how these medicines could transform patient outcomes.
  • Solid tumors

  • Immunology

    Novartis aims to improve outcomes and enhance the lives of those affected by painful and debilitating immunological conditions. As a result, we have already helped transform the standard of care for children and adults suffering from conditions such as psoriatic disease and axial spondyloarthritis, chronic urticaria, and a number of rare autoinflammatory diseases. We continue to focus on discovering and delivering innovative medicines for complex, less-explored immunological diseases where there is significant unmet need, such as hidradenitis suppurativa and Sjögren’s syndrome, lupus and osteoarthritis.
  • Neuroscience

    Novartis has been tackling neurological conditions for more than 80 years. Above all, partnering with patients, healthcare professionals and healthcare systems to deliver life-changing solutions and treatments is at the core of what we do. Together, we can innovate to reimagine neuroscience and improve people’s lives.